|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Clinical Study of Aztreonam |
| Seok Joo Choi, Tae Hoon Ahn,Ja Ryong Koo, Min Ja Kim, Kyung Ho Kang, Seung Cheol Park |
| Department of Internal Medicine, College of Medicine, Korea University, Seoul Korea |
Vol.20 Num.4 (p297~304)
|
|
|
Aztreonam is a new, synthetic, monobactam β-lactam antibiotic with excellent activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Clinical Study of aztreonam was undertaken to a total 20 patients with infection caused by gram-negative bacteria. There were respiratory tract infection (7 patients), urinary tract infection(4), sepsis (3), enteric fever (2), splenic abscess (1), acute cholecystitis (1), spontaneous bacterial peritonitis (1), and infection of an unknown site(1). At doses of 2~4 g per day, aztreonam was administered parenterally, 17 (85%) of a total of 20 patients responded favorably to treatment.
No adverse reactions occurred and a high rate of efficacy make treatment with aztreonam as a single agent feasible. When gram-positive organisms were entercountered or in the cases of serious infection, additional antibiotics were administered for cure. Comparative study and microbiologic evaluation for susceptibility to aztreonam were not performed in this study. And risk, benifits and cost of combination therapy with aztreonam need to be examined in well controlled comparative effecacy studies.
|
|
|
Keywords : |
|
|
|
|
|
|
|
|
